Review of docetaxel in the treatment of gastric cancer

Review

(2887) Views  (681) Full article downloads

Authors: Eric D Tetzlaff, Jonathan D Cheng, Jaffer A Ajani

Published Date September 2008 Volume 2008:4(5) Pages 999 - 1007

DOI: http://dx.doi.org/10.2147/TCRM.S3226

Eric D Tetzlaff¹, Jonathan D Cheng¹, Jaffer A Ajani²

¹Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; ²Gastrointestinal Medical Oncology, M.D. Anderson Cancer Center, Houston, TX, USA

Abstract: Gastric cancer is a global health problem accounting for 800,000 cancer related deaths annually. Often diagnosed at an advanced stage, the treatment of gastric cancer with chemotherapy is directed towards palliating cancer related symptoms with only modest improvements in survival. In addition, no regimen has emerged as a globally accepted standard. New therapeutic options are desperately needed for the treatment of gastric cancer. Docetaxel given in combination has recently emerged as a new option for patients with advanced gastric cancer. This review focuses on the treatment of advanced gastric cancer utilizing docetaxelbased therapy and the novel additions of biotherapy to the existing cytotoxic platforms. In addition, the current investigations of docetaxel for the treatment of potentially curable gastric cancer will be discussed.

Keywords: docetaxel, gastric cancer, chemotherapy, biotherapy